Ginkgo Bioworks vs Maravai LifeSciences
Maravai LifeSciences reported revenue of $186 million in fiscal 2025, about the same as Ginkgo Bioworks' $170 million in fiscal 2025. Ginkgo Bioworks' revenue fell 25.1% in its latest year, and Maravai LifeSciences' fell 28.3%. Ginkgo Bioworks had an operating margin of -185.3%, against -115.9% at Maravai LifeSciences. Free cash flow was −$179 million at Ginkgo Bioworks and −$71 million at Maravai LifeSciences.
Side by side
| Ginkgo Bioworks | Maravai LifeSciences | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $170M | $186M |
| Revenue growth | −25.1% | −28.3% |
| Revenue growth a year, last 5 years | 17.3% | −8.2% |
| Gross margin | — | 18.3% |
| Operating margin | −185.3% | −115.9% |
| Net margin | −183.8% | −70.4% |
| Free cash flow | −$179M | −$71M |
| Free cash flow margin | −105.0% | −38.1% |
| Return on capital | — | −32.0% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 6.9% | 4.7% |
| Last close | $9.61 | $7.54 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | — |
| Piotroski F-score | — | 2 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Ginkgo BioworksMaravai LifeSciences
Operating margin
Percent of revenue
Ginkgo BioworksMaravai LifeSciences
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Ginkgo BioworksMaravai LifeSciences
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Ginkgo Bioworks and Maravai LifeSciences pages.